Brief: Reata Pharmaceuticals, Inc. Announces Fourth Quarter And Full Year 2021 Financial Results And Provides An Update On Clinical Development Programs
28/02/2022 12:26
Feb 28 (Reuters) - Reata Pharmaceuticals Inc RETA.O :
* REATA PHARMACEUTICALS, INC. ANNOUNCES FOURTH QUARTER AND
FULL
YEAR 2021 FINANCIAL RESULTS AND PROVIDES AN UPDATE ON CLINICAL
DEVELOPMENT PROGRAMS
* AT DECEMBER 31, 2021, WE HAD CASH AND CASH EQUIVALENTS OF
$590.3
MILLION
* CASH & CASH EQUIVALENTS WILL BE SUFFICIENT TO ENABLE IT TO
FUND
OPERATIONS THROUGH END OF 2024
* QTRLY LOSS PER SHARE $2.35
* Q4 EARNINGS PER SHARE VIEW $-2.31 -- REFINITIV IBES DATA
Source text for Eikon: ID:nBw1GfcmRa
Further company coverage: RETA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Reata Pharmaceuticals
See all newsReata Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Reata Pharmaceuticals Inc expected to post a loss of $2.88 a share - Earnings Preview
Brief: Biogen Inc Says If Deal Terminated Under Certain Conditions, Reata Will Be Required To Pay Biogen Termination Fee Equal To $264 Mln
U.S. STOCKS ON THE MOVE-US regional banks, Enphase, Centene
Biogen’s $7 bln deal goes smaller and safer